Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 12:29 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 937–960 of 1,869 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: First Treatment Period Clear all

Conditions: Obstructive Sleep Apnea
Interventions: Trillium Full Face Mask, AirFit F20; Device
Lead sponsor: Philips Clinical & Medical Affairs Global; Industry
Eligibility: 21 Years to 85 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: Lehigh Acres, Florida

Conditions: Sly Syndrome, MPS VII, Mucopolysaccharidosis, Mucopolysaccharidosis VII
Interventions: UX003; Drug
Lead sponsor: Ultragenyx Pharmaceutical Inc; Industry
Eligibility: 1 Day to 5 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 3
States / cities: Washington D.C., District of Columbia • New York, New York • Salt Lake City, Utah

Conditions: Hidradenitis Suppurativa
Interventions: Bimekizumab, Placebo; Drug · Other
Lead sponsor: UCB Biopharma SRL; Industry
Eligibility: 18 Years and older
Enrollment: 509 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 24
States / cities: Fountain Valley, California • Thousand Oaks, California • Miami, Florida + 21 more

Conditions: Obesity
Interventions: overfeeding, growth hormone treatment; Other · Drug
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years to 35 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2015
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hypopharyngeal Squamous Cell Carcinoma, Metastatic Laryngeal Squamous Cell Carcinoma, Metastatic Oral Cavity Squamous Cell Carcinoma, Metastatic Oropharyngeal Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Oral Cavity Squamous Cell Carcinoma, Recurrent Oropharyngeal Squamous Cell Carcinoma, Stage IV Hypopharyngeal Carcinoma AJCC v8, Stage IV Laryngeal Cancer AJCC v8, Stage IV Lip and Oral Cavity Cancer AJCC v8, Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8
Interventions: Biopsy Procedure, Biospecimen Collection, Computed Tomography, Ipatasertib, Pembrolizumab; Procedure · Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 20
States / cities: Duarte, California • Irvine, California • Lancaster, California + 12 more

Conditions: Alopecia
Interventions: Platelet Rich Plasma, Minoxidil Foam; Other · Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older · Female only
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Chronic Plaque Psoriasis, Moderate to Severe Plaque Psoriasis
Interventions: Bimekizumab, Adalimumab, Placebo; Drug · Other
Lead sponsor: UCB Biopharma SRL; Industry
Eligibility: 18 Years and older
Enrollment: 478 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 23
States / cities: Glendale, Arizona • Los Angeles, California • San Diego, California + 19 more

Conditions: Parkinson Disease
Interventions: Vibration Session, No vibration session; Device
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 21 Years to 95 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Diffuse Intrinsic Pontine Glioma, Brain Tumor, Recurrent, Solid Tumor, Recurrent, Neuroblastoma, Recurrent, Refractory, Ewing Sarcoma, Recurrent, Refractory, Rhabdomyosarcoma, Recurrent, Refractory, Osteosarcoma, Recurrent, Refractory, Rhabdoid Tumor, Recurrent, Refractory
Interventions: Abemaciclib; Drug
Lead sponsor: Emory University; Other
Eligibility: 2 Years to 25 Years
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 4
States / cities: Phoenix, Arizona • Aurora, Colorado • Atlanta, Georgia

Conditions: Non-muscle Invasive Bladder Cancer
Interventions: TARA-002; Biological
Lead sponsor: Protara Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 131 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2032
U.S. locations: 44
States / cities: Homewood, Alabama • Phoenix, Arizona • Queen Creek, Arizona + 38 more

Conditions: Focal Segmental Glomerulosclerosis
Interventions: RE-021 (Sparsentan), Irbesartan; Drug
Lead sponsor: Travere Therapeutics, Inc.; Industry
Eligibility: 8 Years to 75 Years
Enrollment: 109 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2024
U.S. locations: 28
States / cities: San Diego, California • Torrance, California • Denver, Colorado + 19 more

Conditions: Type 2 Diabetes Mellitus
Interventions: Sotagliflozin (SAR439954), Placebo, Metformin; Drug
Lead sponsor: Lexicon Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 518 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 67
States / cities: Birmingham, Alabama • Phoenix, Arizona • Canoga Park, California + 50 more

Conditions: Irritable Bowel Syndrome With Constipation
Interventions: Linaclotide Dose A, Linaclotide Dose B, Linaclotide Dose C, Linaclotide Approved Adult Dose, Matching Placebo; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 7 Years to 17 Years
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 46
States / cities: Hot Springs, Arkansas • Little Rock, Arkansas • Anaheim, California + 39 more

Conditions: Sickle Cell Disease, Sickle Cell Anemia, SCD
Interventions: Fludarabine, Hematopoietic Stem Cell Transplant (HSCT); Drug · Procedure
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2023
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Posttraumatic Stress Disorder, PTSD, Anxiety, Depression
Interventions: Transcranial Direct Current Stimulation (tDCS), Prolonged Exposure Therapy; Device · Behavioral
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years to 65 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Graft Versus Host Disease
Interventions: LDE225; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 3
States / cities: Boston, Massachusetts

Conditions: Electrocardiogram Repolarisation Abnormality, Gonococcal Infection
Interventions: AZD0914, Moxifloxacin, Placebo; Drug · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 45 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Primary Immunodeficiency Diseases (PID)
Interventions: TAK-881, HYQVIA; Biological
Lead sponsor: Takeda; Industry
Eligibility: 2 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 15
States / cities: Irvine, California • Walnut Creek, California • Denver, Colorado + 12 more

Conditions: Epidermolysis Bullosa (EB), Epidermolysis Bullosa Acquisita, Recessive Dystrophic Epidermolysis Bullosa, Dystrophic Epidermolysis Bullosa
Interventions: Efgartigimod; Biological
Lead sponsor: M. Peter Marinkovich; Other
Eligibility: 12 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Redwood City, California

Conditions: Cognitive Decline, Mucopolysaccharidosis I, Hurler-Scheie Syndrome, Scheie Syndrome, Lysosomal Storage Disease
Interventions: laronidase; Drug
Lead sponsor: Patricia I. Dickson, M.D.; Individual
Eligibility: 6 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 3
States / cities: Oakland, California • Torrance, California • Minneapolis, Minnesota

Conditions: Mild Cognitive Impairment
Interventions: iTBS rTMS; Device
Lead sponsor: Maria I. Lapid, M.D.; Other
Eligibility: 55 Years to 90 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
Interventions: TAK-411; Biological
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 15
States / cities: La Jolla, California • San Francisco, California • Washington D.C., District of Columbia + 12 more

Conditions: Cardiac Failure Aggravated
Interventions: Sotagliflozin, Placebo; Drug
Lead sponsor: Lexicon Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 4
States / cities: La Jolla, California • New Haven, Connecticut • Rochester, Minnesota + 1 more

Conditions: Lateral Canthal Lines
Interventions: MT10109L, Placebo; Drug
Lead sponsor: Medy-Tox; Industry
Eligibility: 18 Years and older
Enrollment: 235 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 9
States / cities: Glendale, Arizona • Newport Beach, California • Coral Gables, Florida + 6 more

Search by objective public record fields.

A Phase II Pilot Study of the Trillium Full Face Mask

Study of UX003 Recombinant Human Beta-Glucuronidase (rhGUS) Enzyme Replacement Treatment in Mucopolysaccharidosis Type 7, Sly Syndrome (MPS 7) Patients Less Than 5 Years of Age

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa

Growth Hormone as a Determinant of Weight Regulation

Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab) in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck

Platelet Rich Plasma Versus Minoxidil Foam for Treatment of Androgenic Alopecia in Women

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis

Optimizing Vibrational Therapy to Improve Gait and Balance in Parkinson's Disease

Abemaciclib in Children With DIPG or Recurrent/Refractory Solid Tumors

Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer

Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis

Efficacy and Safety of Sotagliflozin Versus Placebo in Patients With Type 2 Diabetes Mellitus on Background of Metformin

A Safety and Efficacy Study of a Range of Linaclotide Doses Administered Orally to Children Ages 7-17 Years, With Irritable Bowel Syndrome With Constipation

Hematopoietic Stem Cell Transplant for Sickle Cell Disease

TDCS-Augmented Prolonged Exposure Therapy

Phase I Trial of LDE225 for Steroid-refractory Chronic GVHD After Allogeneic HSCT

Thorough QT/QTC (TQT) Clinical Trial to Evaluate the Effect of Zoliflodacin on Cardiac Repolarization in Healthy Male and Female Subjects

A Study About How TAK-881 is Processed by the Body and Side Effects in People With Primary Immunodeficiency Diseases

Targeting Collagen VII Antibodies in Bullous Diseases Using Efgartigimod IV (VYVGART)

A Study of Intrathecal Enzyme Therapy for Cognitive Decline in MPS I

iTBS rTMS in Mild Cognitive Impairment

A Study of TAK-411 in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

Safety, Tolerability and Pharmacodynamic Activity of Sotagliflozin in Hemodynamically Stable Participants With Worsening Heart Failure

MT10109L in the Treatment of Lateral Canthal Lines